Waters Corp

The New York–based Cantillon Capital Management filed its 13F for the first quarter of 2014. The size of the U.S. long portfolio slightly increased in the quarter, from $4.22 billion to $4.32 billion.

Of the 17 analysts covering Thermo Fisher Scientific (TMO), 14 recommend ” buy” or a higher rating, and three recommend “hold.”

In fiscal 2018 and fiscal 2019, Thermo Fisher Scientific (TMO) is expected to generate revenue of $24.08 billion and $25.19 billion, respectively, compared with revenue of $20.92 billion in fiscal 2017.

In November, of the 19 analysts covering Illumina (ILMN), 14 have given it “buy” or higher ratings, and five have given it “hold” ratings.

Illumina’s cost of product revenue increased from $173.0 million in the third quarter of 2017 to $184.0 million in the third quarter of 2018.

For 2018 and 2019, Illumina is expected to generate revenues of $3.33 billion and $3.80 billion, respectively.

In September, of the 15 analysts covering Waters Corporation (WAT) stock, ten have given it “holds.”

In 2015, ROP’s Radio Frequency Technology segment contributed ~28.9% to its total consolidated revenue and ~30.4% to its consolidated operating profit

Since its inception, Roper Technologies (ROP) has followed an acquisition-based growth strategy. The company has acquired over 50 companies since 1981.

Roper Technologies’ growth strategy includes acquisitions. Its growth largely depends on its ability to acquire and successfully integrate new businesses.

Thermo Fisher Scientific (TMO) has made a number of acquisitions over the years, resulting in the expansion of the company’s product portfolio with the inclusion of a number of premium brands.

Varian Medical Systems (VAR) fell by 1.5% and closed at $76.82 on October 12. The stock fell on profit booking, breaking its three-day upward trend.